A study in the New England Journal of Medicine reports that a gene therapy making retinal cells sensitive to amber light, combined with camera goggles, was safe in ten people blinded by retinitis pigmentosa and gave most of them measurable light sensitivity. It is not a cure, but it is the strongest clinical evidence yet for optogenetic vision restoration.
On Monday, the Nobel Prize in Physiology or Medicine went to Karl Deisseroth, Peter Hegemann and Georg Nagel for light-gated ion channels and optogenetics — the use of algal proteins to switch nerve cells on and off with light. On Wednesday, 7 October, the technique’s first sustained clinical test reached print. A paper in the New England Journal of Medicine (NEJM), “Optogenetic Therapy for Restoring Aspects of Visual Function”, reports results in blind patients treated with an optogenetic gene therapy.
The work was led by José-Alain Sahel of the University of Pittsburgh and Botond Roska of the Institute of Molecular and Clinical Ophthalmology Basel (IOB), with the French company GenSight Biologics and an international team. The same collaboration reported a striking proof of concept in 2021, when a single treated patient regained the ability to locate and count objects.
The disease and the idea
Retinitis pigmentosa is a group of inherited disorders in which the retina’s photoreceptors — the rods and cones that convert light into electrical signals — gradually die. It typically begins with night blindness in childhood or adolescence, progresses to tunnel vision and often leads to legal blindness by early adulthood. More than 80 genes can cause it, which is why gene-replacement therapies, such as the approved treatment for mutations in the RPE65 gene, help only a small subset of patients.
Optogenetics sidesteps the genetic diversity. Even after photoreceptors are lost, the retinal ganglion cells — the neurons whose fibres form the optic nerve — often survive. If those cells could be made to respond to light directly, the eye could send signals to the brain without photoreceptors at all. The therapy does this by delivering, with a harmless viral vector injected into the eye, the gene for ChrimsonR, an engineered light-sensitive ion channel of algal origin that responds best to amber light.
There is a catch: ChrimsonR is far less sensitive than natural photoreceptors and does not respond well to ordinary ambient light. Patients therefore wear goggles fitted with a camera that detects changes in the visual scene and projects corresponding pulses of intense amber light onto the retina.
What the trial found
Ten patients received a single injection into their worse-seeing eye. Safety was the primary endpoint, and the researchers concluded that the combination was safe “within the limits of the study”. Most eye-related adverse events were mild or moderate; one severe event occurred immediately after injection and resolved within minutes.
On efficacy, seven of the ten patients became more sensitive to light, and six reached a predefined threshold for a clinically meaningful improvement. Eight patients completed visual behavioural tests; four of them improved at detecting or locating objects, and more improved at tasks such as finding a doorway or following a line on the floor while wearing the goggles. Measurements of brain activity showed signals consistent with visual information reaching the visual cortex. Patients who spent more time training with the goggles tended to perform better, suggesting that learning to interpret the new signal is part of the therapy.
The limits are equally clear. Normal sight was not restored, and participants could not read or recognise faces. “This study represents an important milestone for optogenetic vision restoration,” said Stefan Futterknecht of IOB, the paper’s second author, who led much of the data analysis.
Reading the result carefully
This is a small, early-stage study without a control group, so it cannot establish how large or durable the benefit is across the wider patient population. Gains measured on laboratory tasks also need to translate into independence in daily life — crossing a road, navigating a home — before the therapy can be judged worthwhile. The goggles add cost and complexity, and their intense light raises questions about long-term retinal safety that only longer follow-up can answer. The 2021 single-patient report generated enormous attention; the new paper’s contribution is to show that the effect is reproducible in several patients and to quantify it.
The field is moving on several fronts. Researchers are engineering more sensitive light-gated proteins that might work without goggles in ordinary daylight, targeting other surviving retinal cells, and combining optogenetics with improved camera processing. Electronic retinal implants, the main alternative, have struggled commercially. Roska and Sahel’s recognition with the 2026 António Champalimaud Vision Award signals how much the ophthalmology community expects from the approach.
Relevance for India
Inherited retinal diseases are a significant cause of childhood and young-adult blindness in India, where consanguineous marriage in some communities raises the frequency of recessive disorders. Population studies in southern India, including the Andhra Pradesh Eye Disease Study by Hyderabad’s L V Prasad Eye Institute, have reported retinitis pigmentosa prevalence higher than the commonly cited global figure of about one in 4,000. Hyderabad’s eye-research community has active programmes in retinal genetics and gene therapy, and a mutation-independent treatment would be particularly valuable in a setting where comprehensive genetic diagnosis is still limited.
Cost will be the decisive question. Gene therapies are among the most expensive medicines in the world, and an optogenetic system adds bespoke hardware. Whether such treatments ever reach Indian patients at scale will depend on further trials, regulatory pathways and, potentially, local manufacturing of viral vectors.
–Dr. Srinayana Kavuri
Key facts
- Paper: “Optogenetic Therapy for Restoring Aspects of Visual Function”, NEJM, 7 Oct 2026 (doi:10.1056/NEJMoa2602215)
- Leads: José-Alain Sahel (University of Pittsburgh), Botond Roska (IOB, Basel); with GenSight Biologics
- Therapy: ChrimsonR gene delivered to retinal ganglion cells by single intraocular injection, plus camera goggles emitting amber light
- Results: 7/10 more light-sensitive (6 clinically meaningful); 4/8 better at detecting or locating objects; one transient severe adverse event
- Limits: no reading or face recognition; small uncontrolled study
